Orthocell Ltd · ASX:OCC
Orthocell — Investor Presentation (July 2026)
17 slides from Orthocell's investor presentation, Jul 14, 2026
Slide 1: Q4 FY26 Investor Presentation
Q4 FY26 Investor Presentation Tuesday 14 July 2026
Slide 2: Disclaimer
Disclaimer This presentation, prepared by Orthocell Ltd (“Company”), does not constitute, representations contained in this presentation, and they do not accept any liability or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy whatsoever (including in negligence
Slide 3: Orthocell at a Glance
Orthocell at a Glance Australian medical technology company with growing international revenue driven by the commercialisation of its flagship nerve repair product, Remplir , in the ~US$2 billion U.S. market1. Fully funded and Remplir U.S. strategy US$3.5 billion1 global investing in sales growth on
Slide 4: Key highlights for the quarter ended 30 June 2026
Key highlights for the quarter ended 30 June 2026 Another very strong quarter, driven by continued execution across all key growth drivers, with U.S. momentum building as RemplirTM expands its commercial footprint and outperforms expectations alongside sustained Australian growth. Win in the Continu
Slide 5: Key performance metrics
Key performance metrics Record revenue of $13.2 million for FY26, up 44% on the prior financial year, and $3.8 million for the June quarter, an increase of 20% on the March quarter, with Q4 FY26 delivering record quarterly revenue and strong performance across all six key metrics, extending a three-
Slide 6: Revenue and cash flow performance
Revenue and cash flow performance Jim Piper Chief Financial Officer
Slide 7: Quarterly and FY26 revenue growth
Quarterly and FY26 revenue growth U.S. Remplir sales continue to grow quarter on quarter, with $0.33M revenue for Q4 FY26, $0.92M since launch and Remplir contributing the vast majority of the 44% year-on-year growth for Orthocell Total Revenue1 by Quarter (A$M) Revenue Bridge: FY25 to FY26 (A$M) 44
Slide 8: Quarterly cash flow summary
Quarterly cash flow summary Sustainable cash reserves are in place to fund the commercialisation of Remplir and support the business to cash flow breakeven, with no additional funding required AUD $M FY26 4Q FY26 3Q FY26 VAR1 Net operating cash is inline with expectations, increased receipts from gr
Slide 9: U.S. Remplir launch update
U.S. Remplir TM launch update John Walker Vice President of U.S. Sales
Slide 10: Remplir significant U.S. market opportunity
Remplir significant U.S. market opportunity TM We are targeting 10% of the 700,0001 US Peripheral nerve repair procedures every year, with Orthocell cash breakeven at ~6,000 procedures Targeting 10%, with an initial focus on Breakeven2 5% of the market 700,000 US Peripheral ~ 60,000 ~10,000 nerve re
Slide 11: FY26 U.S. Remplir commercialisation performance
FY26 U.S. Remplir commercialisation performance TM Commercialisation of Remplir in the U.S. continues to track ahead of expectations 50% Distributor Coverage Distributor coverage exceeded targets by 25%, with 18 distributors now covering approximately 50% of the U.S. population across 20+ states on
Slide 12: U.S. Remplir commercial momentum is building
U.S. Remplir commercial momentum is building TM Exceptional early growth since the first sale of Remplir on 26 June 2025 U.S. Remplir Hospitals Cumulative by Quarter1 U.S. Remplir Surgeons Cumulative by Quarter1 U.S. Remplir Unit Sales by Quarter 70 76 119 +195% +230% +189% Q4FY25 Q1FY26 Q2FY26 Q3FY
Slide 13: FY27 U.S. Remplir commercialisation targets
FY27 U.S. Remplir commercialisation targets TM As commercial penetration continues to build, Orthocell is positioned for a material uplift in U.S. revenue 80% Distributor Coverage Work with our distributor partners to increase our state coverage and create more experts in the field. We are targeting
Slide 14: Other achievements and upcoming catalysts
Other achievements and upcoming catalysts
Slide 15: Achievements and upcoming catalysts
Achievements Nerve repair, made SMRT and upcoming Foundations in place for U.S. growth Achieved catalysts 1 Appoint first and second distributors in CAN Achieved Appoint exclusive distributor in HKG Achieved HK first surgical use Achieved EU+UK submissions lodged Achieved FY25 R&D tax refund ($3M) A
Slide 16: Q&A
Q&A Il \e ortho:c
Slide 17: Authorised for release by the Board of Directors of Orthocell Limited
Authorised for release by The Board of Directors of Orthocell Limited P: +61 8 9360 2888 E: paul.anderson@orthocell.com.au orthocell.com